South Korea-based Lotte Biologics has signed a manufacturing agreement with an Asia-based biotech company for the production of a clinical-stage antibody drug conjugate (ADC) candidate.
This contract marks the first official step in the full-scale operation of the ADC manufacturing facility at the Syracuse Bio Campus in New York, US, which has been under expansion since 2023.
With this, the company is launching its ADC contract development and manufacturing (CDMO) services, designed to meet a wide range of client needs from clinical development to commercial production. It also aims to further enhance the competitiveness of the Syracuse Bio Campus.
Building on this order, the company plans to pursue additional client acquisition opportunities while accelerating the expansion of partnerships to offer comprehensive one-stop services for ADC development and manufacturing. Through these efforts, the company aims to strengthen its position in the ADC therapeutics market and further enhance its standing as a global CDMO.
The ADC manufacturing facility, built with an investment of approximately $100 million, is a cGMP-compliant site that offers end-to-end services. It features an integrated production and purification line, including a conjugation reactor with a capacity of up to 1,000 liters. The facility provides in-house quality control (QC) testing as well as advanced characterization services. In addition, it is equipped with a single-use system that supports the entire process; from antibody preprocessing to automated aseptic filling of drug substances; enabling flexible response to a wide range of client needs.
